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APC-INDEPENDENT EXPANSION OF IMMUNOREGULATORY TR1 CELLS
FROM STEM CELL SOURCES FOR ADOPTIVE IMMUNOTHERAPY
Morales-Tirado, V., Van Der Merwe, M., Luszczek, W., Pillai, A. St.
Jude Children’s Research Hospital, Memphis, TN
Immunotherapy with both adaptive and innate regulatory T cells
facilitates induction of transplant tolerance, including the preven-
tion and treatment of GVHD. Current strategies to expand regula-
tory Tr1 cells from CD31CD41CD25neg conventional T cells
include culture with IL-10 and APCs (Groux, et al., Nature,
1997; Gregori et al., Methods Mol. Biol., 2007) and a non-APC
dependent protocol utilizing anti-CD3 and IL-2 combined with
antibody cross-linking of the innate complement inhibitor I co-
factor protein (CD46) (Kemper et al., Nature, 2003). Optimizing
a robust APC-independent means of Tr1 cell generation is of par-
ticular utility to hematopoietic cell transplant (HCT) immunother-
apy, as it offers potential for large-scale Tr1 cell expansion from
autologous or allogeneic cell sources without need for re-separa-
tion of Tr1 cells from host or donor APCs prior to infusion. To
determine the optimal methods and cellular products for non-
APC-dependent expansion of Tr1 suppressors, we performed
anti-CD46-mediated expansion of Tr1 cells for 21-28 days from
various potential cellular therapy sources. CD31CD41CD25neg
cells were FACS-isolated at . 98% purity and underwent parallel
ex vivo expansions from adult peripheral blood apheresis units (PB-
Tr1), adult bone marrow (BM-Tr1) and cord blood (CB-Tr1) us-
ing low-dose IL-2, anti-CD3, and antibody-crosslinking of
CD46, without addition of IL-10 or APCs, to derive a uniform
population of CD31CD41CD25int/1Foxp3lo cells (. 95% conver-
sion of CD25negFoxp3lo to CD25int/1Foxp3lo cells, regardless of
cellular product type). Differential levels of expansion of Tr1 cells
occurred according to the source of cell product, with greatest fold-
expansion in PB-Tr1 [mean absolute numbers at day 21 fromy105
starting CD31CD41CD25neg cells: PB-Tr1 (n 5 3): 2.5 6 0.8 
107; BM-Tr1 (n 5 2): 7.2  105; CB-Tr1 (n 5 4): 5.6 6 0.3 
105]. By day 14-21 of expansion, PB-Tr1 cells secrete IL-10 and
IL-5, very low levels of IL-2 and IFN-g, and no IL-4 or IL-17
by anti-CD2/CD3/CD28 bead stimulation and Luminex super-
natant assay, and they demonstrate suppressor function against
sorted autologous CFSE-labeled CD31CD41CD25neg responders
in 72-hour MLR using irradiated allogeneic APC stimulators
(Table 1). We are currently optimizing similar protocols for expan-
sion of BM-Tr1 and CB-Tr1 to allow application in tolerance in-
duction and immunotherapy after HCT from each of these cellular
therapy sources.
Table 1. Allo-suppressor MLR (n54) using day 21 PB-Tr1
Responder:
Suppressor
Ratio (± Stim*)
Mean ± SD %
ProliferationP value vs
R only (t-test)P value vs 1:0
(+Stim) (t-test)R only 14.8 ± 3.1 — —
1:0 (+ Stim) 38.0 ± 8.8 0.002 —
1:1 (+ Stim) 21.3 ± 3.5 0.044 0.010
1:5 (+ Stim) 13.8 ± 2.8 0.674 0.003*Stim5 allogeneic 3300 cGy-irradiated APC stimulators170
MULTIVIRUS-SPECIFIC CTL FOR ADOPTIVE TRANSFER USING IN VITRO
PEPMIX STIMULATION
Gerdemann, U., Vera, J.F., Katari, U.L., Keirnan, J.M., Christin, A.S.,
Heslop, H.E., Rooney, C.M., Leen, A.M. Baylor College of Medicine,
Methodist Hospital, and Texas Children’s Hospital, Houston, TX
We and others have shown that viral infections in allo-HSCT
recipients can be prevented/treated by the adoptive transfer of vi-
rus-specific CTL. However, conventional CTL manufacture has
taken . 3 months. We recently developed a protocol to rapidlygenerate CTLs (rCTLs) using DCs nucleofected with viral anti-
gen-encoding DNA plasmids as APCs and expansion in a gas per-
meable bioreactor (G-Rex) in IL71IL4, which reduces
manufacturing time to 16 days. To further streamline production
without affecting potency, we are now assessing whether multivirus
CTL can be generated by directly stimulating donor PBMCs with
clinically applicable pepmixes (15mer peptide libraries) spanning
viral antigens.
We isolated PBMCs from 4 healthy donors and generated rCTL
using plasmid-nucleofected DCs or by directly stimulating bulk
PBMCs using pepmixes spanning the same antigens encoded by
the plasmids (EBV-EBNA1, LMP2, BZLF1; CMV-IE1, pp65
and Adv-Hexon, Penton) (pCTL). Subsequently the activated cells
were expanded as outlined above. We compared the phenotype,
proliferation, specificity and function of each cell population.
There was no significant difference in the rate of expansion
(rCTL vs pCTL, 8.6 vs 7.1 fold). Similarly, both were phenotypi-
cally indistinguishable, with a dominance of CD4 T cells (70.5 vs
74.2%) expressing CD62L (77 vs 61%). Both rCTL and pCTL
were specific for the stimulating antigens as measured by IFNg
ELIspot with a median of 100 vs 55 EBNA1, 45 vs 47 LMP2, 55
vs 32 BZLF1, 195 vs 232 IE1, 3927 vs 4472 pp65, 525 vs 535
Hexon, 372 vs 782 Penton SFC/1x106 CTL. rCTL and pCTL
lysed EBV (16 vs 19%), Adv (27 vs 34%) and CMV targets (42
vs 49% E:T 80:1). Finally, to evaluate whether stimulation using
15mer peptides, which contain all CD8 but possibly not all CD4
epitopes, results in loss of CD41 specificity we generated pCTL
using either 15-or 30mer peptides spanning a region of Hexon pre-
dominantly recognized by CD41 T cells. Phenotypically the CTL
were similar (CD41 56 vs 60%; CD81 21 vs 16%) and epitope
specificity, as evaluated by stimulation with peptide pools, demon-
strated slightly broader specificity using 15-over 30mer peptides
with a mean of 10 vs 7 pools recognized.
In summary, we can efficiently generate polyclonal multivirus
CTLs by directly stimulating PBMCs with pepmixes. This approach
is clinically applicable, requires a starting blood volume of only 15ml,
and reduces manufacturing time to\10 days, with a consequent re-
duction in cost and complexity.171
SENESCENCE OF CULTURED BONE MARROW STROMAL CELLS
Ren, J.1, Stroncek, D.1, Jin, P.1, Castiello, L.1, Tran, K.1,
Balakumaran, A.2, Robey, P.2, Sabatino, M.1 1National Institutes of
Health, Bethesda, MD; 2National Institutes of Health, Bethesda, MD
Bone marrow stromal cell (BMSC) therapy is effective for treat-
ing acute-Graft versus Host Disease. Clinical BMSCs are produced
by serial passage of adherent cells from marrow aspirates. Multiple
passages allow for the production of large quantities of human
BMSCs, but expansion is limited by cell senescence. We assessed
the nature of BMSC changes associated with multiple passages in
order to better understand the nature and impact of senescence
on human BMSCs and to identify potential senescence associated
biomarkers. BMSCs from marrow aspirates of 5 healthy subjects
were cultured in flasks and passed serially until cell growth stopped
between the 8th to 12th passages. Early (passage 1 and 2, n10) and
late passage cells (passages 5 through 11, n15) were selected based
on their replicative lifespan and compared. Senescence was associ-
ated with a change to a flattened morphology and increased senes-
cence associated beta-galactosidase (SA b-gal) staining. The
BMSCs were analyzed by global transcriptome analysis with an
oligonucleotide microarray with .44,000 probes. Unsupervised hi-
erarchical clustering analysis separated the 25 samples into two
clusters, one with all early and a second with all late passage
BMSCs and a total of 1,739 genes were differentially expressed.
Ingenuity pathway analysis revealed that genes highly expressed
in the early passage BMSCs belonged to several immune pathways:
cell-mediated immune response, humoral immune responses, hy-
persensitive responses, and lymphoid tissue structure and develop-
ment. Genes highly expressed in the late passage BMSCs belonged
